Regeneron Pharmaceuticals Business Segments

Business, geographic, and product segment breakdowns

Regeneron Pharmaceuticals generates $14.9B in annual revenue across 4 key segments: Lynozyfic ($11.2M), Other products ($41.4M), (Regeneron's obligation for its share of Sanofi R&D expenses)/reimbursements of R&D expenses, net (-$70.8M), and Reimbursement For Manufacturing Of Commercial Supplies ($631.6M). The company-wide operating margin is 24.32%. Based on the Q1 2026 filing.